[go: up one dir, main page]

Varlow et al., 2021 - Google Patents

Radiofluorination of oxazole-carboxamides for preclinical PET neuroimaging of GSK-3

Varlow et al., 2021

View PDF
Document ID
14981399308104775495
Author
Varlow C
Mossine A
Bernard-Gauthier V
Scott P
Vasdev N
Publication year
Publication venue
Journal of fluorine chemistry

External Links

Snippet

Abstract Glycogen synthase kinase 3 (GSK-3) is an enzyme that is dysregulated in oncology, neurodegeneration, neuroinflammation and several mental health illnesses. As such, GSK-3 is a long-sought after target for positron emission tomography (PET) imaging and …
Continue reading at www.sciencedirect.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Similar Documents

Publication Publication Date Title
Wright et al. Copper-mediated late-stage radiofluorination: five years of impact on preclinical and clinical PET imaging
Mossine et al. Synthesis of diverse 11C-labeled PET radiotracers via direct incorporation of [11C] CO2
Slavik et al. Discovery of a fluorinated 4‐oxo‐quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2
BR112012030935B1 (en) method for the production of f-18 labeled beta-amyloid ligands
Cole et al. Synthesis and evaluation of [11C] PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β)
Varlow et al. Radiofluorination of oxazole-carboxamides for preclinical PET neuroimaging of GSK-3
US20100226853A1 (en) Fluorine-18 derivatives of dasatinib and uses thereof
Berroterán-Infante et al. (R)-[18F] NEBIFQUINIDE: A promising new PET tracer for TSPO imaging
Saccomanni et al. Design, synthesis and preliminary evaluation of 18F-labelled 1, 8-naphthyridin-and quinolin-2-one-3-carboxamide derivatives for PET imaging of CB2 cannabinoid receptor
Bai et al. Synthesis and characterization of a new Positron emission tomography probe for orexin 2 receptors neuroimaging
Lee et al. Synthesis and evaluation of 6-(3-[18F] fluoro-2-hydroxypropyl)-substituted 2-pyridylbenzothiophenes and 2-pyridylbenzothiazoles as potential PET tracers for imaging Aβ plaques
Tran et al. Synthesis and evaluation of novel potent TSPO PET ligands with 2-phenylpyrazolo [1, 5-a] pyrimidin-3-yl acetamide
Wang et al. Synthesis and characterization of the two enantiomers of a chiral sigma-1 receptor radioligand:(S)-(+)-and (R)-(-)-[18F] FBFP
Rodnick et al. Novel fluorine-18 PET radiotracers based on flumazenil for GABAA imaging in the brain
JP7209970B2 (en) 2-[5-(imidazol-1-ylmethyl)pyridin-3-yl]benzimidazole derivative compound and medicine containing the same
Luo et al. Synthesis and preclinical evaluation of 11C-labeled 7-Oxo-2, 4, 5, 7-tetrahydro-6H-pyrazolo [3, 4-c] pyridine radioligands for RIPK1 positron emission tomography imaging
Hugenberg et al. Radiolabeled hydroxamate-based matrix metalloproteinase inhibitors: how chemical modifications affect pharmacokinetics and metabolic stability
Chassé et al. Spirocyclic Iodonium Ylides for Fluorine‐18 Radiolabeling of Non‐Activated Arenes: From Concept to Clinical Research
Xu et al. Synthesis and characterization of carbon-11 labeled iloperidone for imaging of α1-adrenoceptor in brain
L'Estrade et al. Radiosynthesis and preclinical evaluation of [11C] Cimbi‐701–Towards the imaging of cerebral 5‐HT7 receptors
Xiao et al. Radiosynthesis and evaluation of a novel 18F-labeled tracer for PET imaging of glycogen synthase kinase 3
Langer et al. High specific radioactivity (1R, 2S)-4-[18F] fluorometaraminol: a PET radiotracer for mapping sympathetic nerves of the heart
Chen et al. Synthesis and evaluation of novel F-18 labeled 4-aminoquinazoline derivatives: Potential PET imaging agents for tumor detection
Fernández et al. 3-(Benzyloxy)-1-(5-[18F] fluoropentyl)-5-nitro-1 H-indazole: a PET radiotracer to measure acetylcholinesterase in brain
Gao et al. Evaluation of [11C] hemicholinium-15 and [18F] hemicholinium-15 as new potential PET tracers for the high-affinity choline uptake system in the heart